TapewireFind a company

person · Reporting owner

LAMATTINA JOHN L

Disclosed activity across 5 companies

Tapewire entity
17238
SEC CIK
0001216074

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Immunome Inc.IMNM · Entity 4219DirectorJune 08, 2023June 12, 2023
LIGAND PHARMACEUTICALS INCLGND · Entity 3825DirectorJune 10, 2026June 12, 2026
Larimar Therapeutics, Inc.ZFGN · Entity 5634DirectorJune 26, 2019June 27, 2019
THERMO FISHER SCIENTIFIC INC.TMO · Entity 2836DirectorMay 24, 2006May 25, 2006

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Immunome Inc.

Report date June 08, 2023 · Filed June 12, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.84 · Expires 2033-06-08Direct6,500 Reported balance After 2023-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-08 · Grant · Acquired 6,500 · Balance 6,500

F1: The shares subject to the options shall vest 25% every quarter after the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the options shall vest 25% every quarter after the grant date.

LIGAND PHARMACEUTICALS INC

Report date June 10, 2026 · Filed June 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect26,969 Ending reported balance After 2026-06-10 transaction · row 4
4 source rows · reconciled sequence

Row 1 · 2026-06-10 · Sale · Disposed 257 · Balance 31,303

F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Row 2 · 2026-06-10 · Sale · Disposed 232 · Balance 31,071

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Row 3 · 2026-06-10 · Sale · Disposed 697 · Balance 30,374

F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Row 4 · 2026-06-10 · Sale · Disposed 3,405 · Balance 26,969

F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Larimar Therapeutics, Inc.

Report date June 26, 2019 · Filed June 27, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2029-06-26Direct27,000 Reported balance After 2019-06-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-06-26 · Grant · Acquired 27,000 · Balance 27,000

F1: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company.

Filing footnotes · ownership attribution and instrument terms

F1: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company.

THERMO FISHER SCIENTIFIC INC.

Report date May 24, 2006 · Filed May 25, 2006

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.75 · Expires 2013-05-24Direct10,500 Reported balance After 2006-05-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2006-05-24 · Grant · Acquired 10,500 · Balance 10,500

F1: The option vests in three equal annual installments beginning on May 24, 2007.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in three equal annual installments beginning on May 24, 2007.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PFIZER INC

Report date October 15, 2007 · Filed October 17, 2007

Section 16 reporting ended · disclosed 2007-10-17. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Phantom Stock Units SSPSEC Table II · derivative / convertible securityDirect57,875 Reported balance After 2007-10-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2007-10-15 · Grant · Acquired 214 · Balance 57,875

F1: Each unit represents one phantom share of common stock.

F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Filing footnotes · ownership attribution and instrument terms

F1: Each unit represents one phantom share of common stock.

F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 10, 2026 Filed Jun 12, 2026 21:26 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 SaleCommon Stock 3,405 $251.62 $856,751.80
Disclosure

SEC source: 0002001011-26-000102 · edgardoc.xml · nonDerivative · entry 4

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,969

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:26 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 SaleCommon Stock 697 $249.53 $173,924.22
Disclosure

SEC source: 0002001011-26-000102 · edgardoc.xml · nonDerivative · entry 3

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,374

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:26 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 SaleCommon Stock 232 $248.11 $57,561.78
Disclosure

SEC source: 0002001011-26-000102 · edgardoc.xml · nonDerivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,071

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:26 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 SaleCommon Stock 257 $247.22 $63,536.49
Disclosure

SEC source: 0002001011-26-000102 · edgardoc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,303

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 05, 2026 Filed Jun 9, 2026 23:41 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 2,938 $0.00 Strike: $237.00 $0.00
Disclosure

SEC source: 0002001011-26-000099 · edgardoc.xml · derivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,938

Underlying: Common Stock · 2,938 shares

Expires 2036-06-05

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
June 05, 2026 Filed Jun 9, 2026 23:41 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantCommon Stock 836 $0.00 $0.00
Disclosure

SEC source: 0002001011-26-000099 · edgardoc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,560

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
March 06, 2026 Filed Mar 31, 2026 21:53 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 2,161 $0.00 Strike: $114.15 $0.00
Disclosure

SEC source: 0002001011-26-000036 · primary_doc.xml · derivative · entry 3

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,161 shares

Expires 2028-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This Option was previously reported as a Grant of 2,474 shares, which vested in full on June 6, 2019, at an exercise price of $195.91 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.

Read SEC document
March 06, 2026 Filed Mar 31, 2026 21:53 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 SaleCommon Stock 2,161 $200.76 $433,842.36
Disclosure

SEC source: 0002001011-26-000036 · primary_doc.xml · nonDerivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,724

Read SEC document
March 06, 2026 Filed Mar 31, 2026 21:53 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionCommon Stock 2,161 $114.15 $246,678.15
Disclosure

SEC source: 0002001011-26-000036 · primary_doc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,885

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:44 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 2,034 $0.00 Strike: $69.51 $0.00
Disclosure

SEC source: 0002001011-25-000097 · edgardoc.xml · derivative · entry 6

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,034 shares

Expires 2026-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2017, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.

Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:44 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 2,145 $0.00 Strike: $66.13 $0.00
Disclosure

SEC source: 0002001011-25-000097 · edgardoc.xml · derivative · entry 5

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,145 shares

Expires 2027-05-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This Option was previously reported as a Grant of 2,456 shares, which vested in full on May 25, 2018, at an exercise price of $113.5000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.

Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:44 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 SaleCommon Stock 2,034 $205.45 $417,885.30
Disclosure

SEC source: 0002001011-25-000097 · edgardoc.xml · nonDerivative · entry 4

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,724

Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:44 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionCommon Stock 2,034 $69.51 $141,383.34
Disclosure

SEC source: 0002001011-25-000097 · edgardoc.xml · nonDerivative · entry 3

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,758

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:44 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 SaleCommon Stock 2,145 $205.45 $440,690.25
Disclosure

SEC source: 0002001011-25-000097 · edgardoc.xml · nonDerivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,724

Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:44 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionCommon Stock 2,145 $66.13 $141,848.85
Disclosure

SEC source: 0002001011-25-000097 · edgardoc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,869

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 06, 2025 Filed Jun 10, 2025 23:24 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 5,783 $0.00 Strike: $105.99 $0.00
Disclosure

SEC source: 0002001011-25-000044 · edgardoc.xml · derivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,783

Underlying: Common Stock · 5,783 shares

Expires 2035-06-06

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
June 06, 2025 Filed Jun 10, 2025 23:24 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantCommon Stock 1,209 $0.00 $0.00
Disclosure

SEC source: 0002001011-25-000044 · edgardoc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,724

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
November 27, 2024 Filed Dec 3, 2024 01:05 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 2,406 $0.00 Strike: $52.30 $0.00
Disclosure

SEC source: 0002001011-24-000093 · edgardoc.xml · derivative · entry 3

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,406 shares

Expires 2025-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This Option was previously reported as a Grant of 2,754 shares on April 24, 2015, which vested in full on April 24, 2016, at an exercise price of $89.7500 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.

Read SEC document
November 27, 2024 Filed Dec 3, 2024 01:05 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 SaleCommon Stock 2,406 $123.65 $297,501.90
Disclosure

SEC source: 0002001011-24-000093 · edgardoc.xml · nonDerivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,515

Read SEC document
November 27, 2024 Filed Dec 3, 2024 01:05 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionCommon Stock 2,406 $52.30 $125,833.80
Disclosure

SEC source: 0002001011-24-000093 · edgardoc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,921

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 14, 2024 Filed Jun 19, 2024 01:27 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 5,444 $0.00 Strike: $80.06 $0.00
Disclosure

SEC source: 0002001011-24-000059 · edgardoc.xml · derivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,444

Underlying: Common Stock · 5,444 shares

Expires 2034-06-14

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
June 14, 2024 Filed Jun 19, 2024 01:27 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantCommon Stock 1,252 $0.00 $0.00
Disclosure

SEC source: 0002001011-24-000059 · edgardoc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,515

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
June 09, 2023 Filed Jun 13, 2023 22:55 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 5,461 $0.00 Strike: $73.76 $0.00
Disclosure

SEC source: 0000886163-23-000042 · edgardoc.xml · derivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,461

Underlying: Common Stock · 5,461 shares

Expires 2033-06-09

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
June 09, 2023 Filed Jun 13, 2023 22:55 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantCommon Stock 1,142 $0.00 $0.00
Disclosure

SEC source: 0000886163-23-000042 · edgardoc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,263

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
June 08, 2023 Filed Jun 12, 2023 20:54 UTC Immunome Inc. IMNM · Entity 4219 GrantStock Option (Right to Buy) · Derivative 6,500 $0.00 Strike: $4.84 $0.00
Disclosure

SEC source: 0001104659-23-070402 · tm2318426-6_4seq1.xml · derivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 6,500 shares

Expires 2033-06-08

F1 · derivative.exercise_date: The shares subject to the options shall vest 25% every quarter after the grant date.

Read SEC document
January 15, 2023 Filed Jan 17, 2023 11:29 UTC Immunome Inc. IMNM · Entity 4219 GrantCommon Stock 15,125 $4.00 $60,500.00
Disclosure

SEC source: 0001104659-23-004007 · tm233517-3_4seq1.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,953

F1 · price: The shares of Common Stock were issued to the Reporting Person pursuant to the Issuer's 2020 Equity Compensation Plan in lieu of the non-employee director board and committee cash retainers of $60,500 in the aggregate owed to the Reporting Person for service on the board of directors in 2022.

Read SEC document
December 22, 2022 Filed Dec 27, 2022 23:28 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 4,484 $0.00 Strike: $67.03 $0.00
Disclosure

SEC source: 0000899243-22-039404 · doc4.xml · derivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,484

Underlying: Common Stock · 4,484 shares

Expires 2032-12-22

F1 · derivative.exercise_date: Grant to reporting person of stock options that will vest and become exercisable on December 22, 2023.

Read SEC document
June 16, 2022 Filed Jun 21, 2022 22:01 UTC Immunome Inc. IMNM · Entity 4219 GrantStock Option (Right to Buy) · Derivative 6,500 $0.00 Strike: $2.62 $0.00
Disclosure

SEC source: 0001104659-22-073094 · tm2218674-2_4seq1.xml · derivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 6,500 shares

Expires 2032-06-16

F1 · derivative.exercise_date: The shares subject to the options shall vest 25% every quarter after the grant date.

Read SEC document
June 10, 2022 Filed Jun 13, 2022 22:45 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 4,340 $0.00 Strike: $79.29 $0.00
Disclosure

SEC source: 0000886163-22-000079 · edgardoc.xml · derivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,340

Underlying: Common Stock · 4,340 shares

Expires 2032-06-10

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
June 10, 2022 Filed Jun 13, 2022 22:45 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantCommon Stock 1,004 $0.00 $0.00
Disclosure

SEC source: 0000886163-22-000079 · edgardoc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,402

F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
November 16, 2021 Filed Nov 17, 2021 22:06 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 4,835 $0.00 Strike: $32.30 $0.00
Disclosure

SEC source: 0000886163-21-000136 · edgardoc.xml · derivative · entry 3

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,835 shares

Expires 2023-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 11, 2013, and fully vested on the first anniversary of the grant date.

Read SEC document
November 16, 2021 Filed Nov 17, 2021 22:06 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 SaleCommon Stock 4,835 $161.86 $782,579.08
Disclosure

SEC source: 0000886163-21-000136 · edgardoc.xml · nonDerivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,398

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.36 to $164.12, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
November 16, 2021 Filed Nov 17, 2021 22:06 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionCommon Stock 4,835 $32.30 $156,170.50
Disclosure

SEC source: 0000886163-21-000136 · edgardoc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,233

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 04, 2021 Filed Jun 8, 2021 01:24 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 3,269 $0.00 Strike: $115.39 $0.00
Disclosure

SEC source: 0000886163-21-000089 · edgardoc.xml · derivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,269

Underlying: Common Stock · 3,269 shares

Expires 2031-06-04

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
June 04, 2021 Filed Jun 8, 2021 01:24 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantCommon Stock 630 $0.00 $0.00
Disclosure

SEC source: 0000886163-21-000089 · edgardoc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,398

F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
May 28, 2021 Filed Jun 2, 2021 00:01 UTC Immunome Inc. IMNM · Entity 4219 GrantStock Option (Right to Buy) · Derivative 3,750 $0.00 Strike: $20.92 $0.00
Disclosure

SEC source: 0001104659-21-075261 · tm2118079d3_4seq1.xml · derivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,750

Underlying: Common Stock · 3,750 shares

Expires 2031-05-28

F1 · derivative.exercise_date: The shares subject to the option shall vest 25% every quarter after the grant date.

Read SEC document
May 24, 2021 Filed May 27, 2021 01:26 UTC Immunome Inc. IMNM · Entity 4219 PurchaseCommon Stock 5,102 $18.58 $94,795.16
Disclosure

SEC source: 0001104659-21-072617 · tm2117684-1_4seq1.xml · nonDerivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,828

Read SEC document
May 24, 2021 Filed May 27, 2021 01:26 UTC Immunome Inc. IMNM · Entity 4219 PurchaseCommon Stock 338 $18.44 $6,232.72
Disclosure

SEC source: 0001104659-21-072617 · tm2117684-1_4seq1.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,726

Read SEC document
November 03, 2020 Filed Nov 6, 2020 01:12 UTC Immunome Inc. IMNM · Entity 4219 GrantStock Option (Right to Buy) · Derivative 7,500 $0.00 Strike: $11.38 $0.00
Disclosure

SEC source: 0001104659-20-122029 · a4.xml · derivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2030-11-03

F1 · security: One-twelfth (1/12th) of the shares subject to the option shall vest on February 3, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest every three months thereafter.

F1 · derivative.exercise_date: One-twelfth (1/12th) of the shares subject to the option shall vest on February 3, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest every three months thereafter.

Read SEC document
October 06, 2020 Filed Oct 8, 2020 22:11 UTC Immunome Inc. IMNM · Entity 4219 ConversionWarrant (right to buy) · Derivative 11,111 $0.00 Strike: $9.00 $0.00
Disclosure

SEC source: 0001209191-20-054315 · doc4.xml · derivative · entry 4

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,111

Underlying: Common Stock · 11,111 shares

Expires 2023-06-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F3 · derivative.exercise_date: Immediately exercisable.

Read SEC document
October 06, 2020 Filed Oct 8, 2020 22:11 UTC Immunome Inc. IMNM · Entity 4219 ConversionWarrant (right to buy) · Derivative 11,111 $0.00 Strike: $9.00 $0.00
Disclosure

SEC source: 0001209191-20-054315 · doc4.xml · derivative · entry 3

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Series A Convertible Preferred Stock · 11,111 shares

Expires 2023-06-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F3 · derivative.exercise_date: Immediately exercisable.

Read SEC document
October 06, 2020 Filed Oct 8, 2020 22:11 UTC Immunome Inc. IMNM · Entity 4219 ConversionSeries A Convertible Preferred Stock · Derivative 46,388 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-054315 · doc4.xml · derivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 46,388 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

Read SEC document
October 06, 2020 Filed Oct 8, 2020 22:11 UTC Immunome Inc. IMNM · Entity 4219 ConversionCommon Stock 46,388 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-054315 · doc4.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,388

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

Read SEC document
June 10, 2020 Filed Jun 12, 2020 22:32 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 2,468 $0.00 Strike: $117.58 $0.00
Disclosure

SEC source: 0000886163-20-000075 · edgardoc.xml · derivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,468

Underlying: Common Stock · 2,468 shares

Expires 2030-06-10

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
June 10, 2020 Filed Jun 12, 2020 22:32 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantCommon Stock 831 $0.00 $0.00
Disclosure

SEC source: 0000886163-20-000075 · edgardoc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,768

F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
August 01, 2019 Filed Aug 5, 2019 23:00 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 2,500 $0.00 Strike: $32.30 $0.00
Disclosure

SEC source: 0000886163-19-000138 · edgardoc.xml · derivative · entry 3

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,835

Underlying: Common Stock · 2,500 shares

Expires 2023-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 11, 2013, and fully vested on the first anniversary of the grant date.

Read SEC document
August 01, 2019 Filed Aug 5, 2019 23:00 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Tax withholdingCommon Stock 847 $95.58 $80,958.29
Disclosure

SEC source: 0000886163-19-000138 · edgardoc.xml · nonDerivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,937

F1 · shares: Represents shares withheld by the Issuer in payment of the exercise price of options.

Read SEC document
August 01, 2019 Filed Aug 5, 2019 23:00 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionCommon Stock 2,500 $32.30 $80,750.00
Disclosure

SEC source: 0000886163-19-000138 · edgardoc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,784

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 26, 2019 Filed Jun 27, 2019 19:33 UTC Larimar Therapeutics, Inc. ZFGN · Entity 5634 GrantStock Option (Right to Buy) · Derivative 27,000 $0.00 Strike: $1.25 $0.00
Disclosure

SEC source: 0000899243-19-018474 · doc4.xml · derivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2029-06-26

F1 · derivative.exercise_date: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company.

Read SEC document
June 06, 2019 Filed Jun 7, 2019 22:46 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 4,071 $0.00 Strike: $113.59 $0.00
Disclosure

SEC source: 0000886163-19-000104 · edgardoc.xml · derivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,071

Underlying: Common Stock · 4,071 shares

Expires 2029-06-06

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.